193 related articles for article (PubMed ID: 16550508)
1. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
[TBL] [Abstract][Full Text] [Related]
2. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
3. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
[TBL] [Abstract][Full Text] [Related]
4. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
5. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
6. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
7. Primary amyloidosis of the kidney.
Shafique S; Wetmore J; Almehmi A
W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
Koh LP; Koh MB; Ng HY; Hwang WY; Goh YT; Linn YC; Ng HJ; Chuah CT; Tan KW; Loh YS; Tan DC; Tan PH; Tan PH
Biol Blood Marrow Transplant; 2006 Aug; 12(8):887-90. PubMed ID: 16864060
[No Abstract] [Full Text] [Related]
9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
12. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
13. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
[TBL] [Abstract][Full Text] [Related]
14. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
Sanchorawala V; Seldin DC
Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
[TBL] [Abstract][Full Text] [Related]
15. Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
Resnick IB; Abdul Hai A; Shapira MY; Bitan M; Hershkovitz E; Schwartz A; Ben-Harush M; Or R; Slavin S; Kapelushnik J
Clin Transplant; 2005 Dec; 19(6):840-7. PubMed ID: 16313334
[TBL] [Abstract][Full Text] [Related]
16. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
17. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
[TBL] [Abstract][Full Text] [Related]
18. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
[TBL] [Abstract][Full Text] [Related]
20. [Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children].
Inoue M; Yasui M; Sawada A; Koyama M; Kondo O; Miyamura T; Higuchi B; Kouroki M; Ishihara T; Kawa K
Rinsho Ketsueki; 2007 Nov; 48(11):1470-7. PubMed ID: 18080504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
